Adjuvant therapy guided by molecular classification in endometrial cancer: survival benefit and safety profile.

ABSTRACT:

Objectives

To evaluate the effect of molecular classification-based postoperative adjuvant therapy on survival outcomes and treatment safety in patients with endometrial cancer.

Methods

This retrospective study included 208 endometrial cancer patients treated between January 2022 and January 2025. Patients were divided into a control group (n = 102), receiving conventional adjuvant therapy, and an observation group (n = 106), receiving molecular classification-based personalized regimens. The primary endpoints were disease-free survival (DFS) and overall survival (OS). Secondary measures included objective response, treatment-related toxicity, treatment delivery factors, patient-reported outcomes, and next-generation sequencing of circulating tumor DNA (ctDNA). Multivariate

SUBMITTER: Liu L 

PROVIDER: S-EPMC12709356 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature